Jingjing Liu

Jingjing Liu

Auto-generated profile, based on publicly available information

Jingjing Liu

Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Pharmacological Research
Verified
Journal Article
Closed access
WJWanghui Jing
Wanghui Jing
SDSijing Dong
Sijing Dong
XLXialin Luo
Xialin Luo
JLJingjing Liu
Jingjing Liu
BWBin Wei
Bin Wei
HAITAO LYUHAITAO LYU
HAITAO LYU

1 June 2020 in Pharmacological Research
Verified
Journal Article
Closed access
XLXialin Luo
Xialin Luo
JLJingjing Liu
Jingjing Liu
HWHuaizhi Wang
Huaizhi Wang
HAITAO LYUHAITAO LYU
HAITAO LYU

21 July 2020 in Journal of Proteome Research
Verified
Journal Article
Closed access
JLJingjing Liu
Jingjing Liu
XLXialin Luo
Xialin Luo
RGRui Guo
Rui Guo
WJWanghui Jing
Wanghui Jing
HAITAO LYUHAITAO LYU
HAITAO LYU

3 February 2016 in Future Oncology
Verified
Journal Article
Closed access
YCYing Cheng
Ying Cheng
XLXiao-Qing Liu
Xiao-Qing Liu
YFYun Fan
Yun Fan
YLYunpeng Liu
Yunpeng Liu
YLYi Liu
Yi Liu
CWChun-Jiao Wu
Chun-Jiao Wu
Aims: As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC. Materials & methods: Blood CTC counts were determined using the CellSearch® system at baseline, after the second cycle of chemotherapy, and on disease progression. Results & conclusion: Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy ≤3 months) and sensitive disease (response to initial therapy >3 months).

8 September 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
XWXinyu Wang
Xinyu Wang
YWyan wang
yan wang
QWQiong Wu
Qiong Wu
JLJing-Jing Liu
Jing-Jing Liu
YLYu Liu
Yu Liu
MYMin Yang
Min Yang
Clinical tracking of chimeric antigen receptor (CAR) T cells in vivo by positron emission tomography (PET) imaging is an area of intense interest. But the long-lived positron emitter-labeled CAR T cells stay in the liver and spleen for days or even weeks. Thus, the excessive absorbed effective dose becomes a major biosafety issue leading it difficult for clinical translation. In this study we used 68Ga, a commercially available short-lived positron emitter, to label CAR T cells for noninvasive cell tracking in vivo. CAR T cells could be tracked in vivo by 68Ga-PET imaging for at least 6 h. We showed a significant correlation between the distribution of 89Zr and 68Ga-labeled CAR T cells in the same tissues (lungs, liver, and spleen). The distribution and homing behavior of CAR T cells at the early period is highly correlated with the long-term fate of CAR T cells in vivo. And the effective absorbed dose of 68Ga-labeled CAR T cells is only one twenty-fourth of 89Zr-labeled CAR T cells, which was safe for clinical translation. We conclude the feasibility of 68Ga instead of 89Zr directly labeling CAR T cells for noninvasive tracking of the cells in vivo at an early stage based on PET imaging. This method provides a potential solution to the emerging need for safe and practical PET tracer for cell tracking clinically.

5 November 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SDShuyan Dai
Shuyan Dai
JLJingjing Liu
Jingjing Liu
XSXiaofei Sun
Xiaofei Sun
NWNing Wang
Ning Wang
Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the ovarian cancer have not been fully elucidated. Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity, small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC. G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression. G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer.